➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Harvard Business School
McKesson
Boehringer Ingelheim

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

ELOCON Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Elocon, and when can generic versions of Elocon launch?

Elocon is a drug marketed by Merck Sharp Dohme and is included in three NDAs.

The generic ingredient in ELOCON is mometasone furoate. There are thirty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

US ANDA Litigation and Generic Entry Outlook for Elocon

A generic version of ELOCON was approved as mometasone furoate by PERRIGO NEW YORK on March 18th, 2002.

  Start Trial

Drug patent expirations by year for ELOCON
Drug Prices for ELOCON

See drug prices for ELOCON

Recent Clinical Trials for ELOCON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
LEO PharmaPhase 1
University of OuluPhase 4
Schering-PloughPhase 4

See all ELOCON clinical trials

Pharmacology for ELOCON
Paragraph IV (Patent) Challenges for ELOCON
Tradename Dosage Ingredient NDA Submissiondate
ELOCON LOTION;TOPICAL mometasone furoate 019796 2004-06-10
ELOCON CREAM;TOPICAL mometasone furoate 019625

US Patents and Regulatory Information for ELOCON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme ELOCON mometasone furoate CREAM;TOPICAL 019625-001 May 6, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme ELOCON mometasone furoate OINTMENT;TOPICAL 019543-001 Apr 30, 1987 DISCN Yes No   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme ELOCON mometasone furoate CREAM;TOPICAL 019625-002 Apr 19, 2013 DISCN Yes No   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme ELOCON mometasone furoate LOTION;TOPICAL 019796-001 Mar 30, 1989 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ELOCON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme ELOCON mometasone furoate CREAM;TOPICAL 019625-001 May 6, 1987   Start Trial   Start Trial
Merck Sharp Dohme ELOCON mometasone furoate LOTION;TOPICAL 019796-001 Mar 30, 1989   Start Trial   Start Trial
Merck Sharp Dohme ELOCON mometasone furoate OINTMENT;TOPICAL 019543-001 Apr 30, 1987   Start Trial   Start Trial
Merck Sharp Dohme ELOCON mometasone furoate CREAM;TOPICAL 019625-001 May 6, 1987   Start Trial   Start Trial
Merck Sharp Dohme ELOCON mometasone furoate LOTION;TOPICAL 019796-001 Mar 30, 1989   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for ELOCON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0057401 SPC/GB93/085 United Kingdom   Start Trial SPC/GB93/085, EXPIRES: 20050621
0057401 94C0002 Belgium   Start Trial PRODUCT NAME: MOMETASONI FUROAS; NAT. REG.: 304 S 131 F 7 19930813; FIRST REG.: GR 10681/89 19900622
0548114 SPC/GB97/064 United Kingdom   Start Trial PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
0057401 94C0003 Belgium   Start Trial PRODUCT NAME: MOMETASONI FUROAS; NAT REG.: 304 S 132 F 11 19930813; FIRST REG.: GR 10683/89 19900622
0057401 94C0004 Belgium   Start Trial PRODUCT NAME: MOMETASONI FUROAS; NAT REG.: 304 S 133 F 7 19930813; FIRST REG.: GR 10682/89 19900622
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.